Remote Ischemic Conditioning for the Treatment of Resistant Hypertension

Status Not yet recruiting

Clinical Trial Summary

This study aims to explore the efficacy and safety of remote ischemia adaptation for the treatment of resistant hypertension.

Clinical Trial Description

Resistant hypertension is defined as a blood pressure of 140/90 mmHg or higher despite adherence to at least three antihypertensive drugs (including one diuretic), accounting for 20% to 30% of patients with hypertension. Compared with patients with well-controlled blood pressure, the cardiovascular risk of resistant hypertension is increased by about 50%. Limb remote ischemic conditioning (LRIC) triggers endogenous protective effects through transient and repeated ischemia in the limb to protect remote tissues and organs. The mechanisms of LRIC involve the regulation of the autonomic nervous system, the release of humoral factors, improvement of vascular endothelial function, and modulation of immune/inflammatory responses, which can antagonize the pathogenesis of hypertension through multiple pathways to lead to a drop in BP theoretically. This theory has been preliminarily confirmed by several small sample-size studies in non-resistant hypertension. This study aims to explore the efficacy and safety of remote ischemia adaptation for the treatment of resistant hypertension. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05426707
Study type	Interventional
Source	Capital Medical University
Contact	Xunming Ji, MD, PhD
Phone	83199430
Email	jixm@ccmu.edu.cn
Status	Not yet recruiting
Phase	N/A
Start date	October 1, 2022
Completion date	March 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05545059` - Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension	Phase 3
Not yet recruiting	`NCT04388124` - VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION	Phase 2
Withdrawn	`NCT01939392` - Rapid Renal Sympathetic Denervation for Resistant Hypertension II	Phase 2/Phase 3
Recruiting	`NCT06228677` - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting	`NCT04213963` - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Recruiting	`NCT05563077` - Aerobic Exercise and Resistant Hypertension	N/A
Recruiting	`NCT03758196` - Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension（RSDARH）	N/A
Active, not recruiting	`NCT03179800` - CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™	N/A
Completed	`NCT04519658` - A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)	Phase 2
Not yet recruiting	`NCT05552300` - Superselective Adrenal Arterial Embolization for Resistant Hypertension	N/A
Completed	`NCT04345198` - Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension	N/A
Active, not recruiting	`NCT05562934` - An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.	Phase 2
Recruiting	`NCT06034743` - A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension	Phase 3
Withdrawn	`NCT02926495` - Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.	N/A
Active, not recruiting	`NCT02670681` - Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects	N/A
Completed	`NCT02572024` - The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)	N/A
Terminated	`NCT02295683` - Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
Completed	`NCT02001350` - Carotid Ultrasound Study	N/A
Recruiting	`NCT04331691` - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension	Phase 4
Recruiting	`NCT04637152` - Sacubitril/Valsartan in Resistant Hypertension	Phase 2